Revitalist Releases Benefits Program Giving Access To All for Ketamine Therapies Changing the Narrative of Mental Health to Risk MitigationNovember 25, 2024 9:59 AM EST | Source: Revitalist Lifestyle & Wellness LtdVancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) (the "Company") announces release of a benefits plan to those seeking ketamine therapies through member subscription. This will help directly ...

Core Insights - The stock performance of Tyson Foods and Cal-Maine Foods has diverged significantly, with Tyson experiencing a decline while Cal-Maine has seen substantial gains [2][14]. Tyson Foods - Tyson Foods, the largest beef and chicken producer in the U.S., reported a 1.6% year-over-year revenue increase to $13.35 billion in Q3 2024, surpassing consensus estimates of $13.21 billion [3][4]. - The beef segment generated $5.24 billion in revenue, up 1.4% year-over-year, while pork revenue grew by 12.6% year-over-year to $1.46 billion. Chicken revenue was $4.07 billion, down 3.7% year-over-year [4]. - Chicken remains the most profitable segment for Tyson, generating $244 million in GAAP profit, compared to losses in beef and pork [4]. - The USDA forecasts a slight increase in domestic protein production for 2023, with Tyson expecting a 2% decline in beef production and an adjusted operating loss of $300 million to $400 million for fiscal 2024 [5][6]. - Chicken consumption in the U.S. reached a record high of 101.1 pounds per person in 2023, projected to rise to 103.2 pounds in 2024 [6]. - Tyson's stock has a forward price-earnings ratio of 20.86, with a consensus price target of $59.00, indicating potential upside [7][14]. Cal-Maine Foods - Cal-Maine Foods, the largest egg producer in the U.S., reported a 71.1% year-over-year revenue increase to $785.9 million in its fiscal Q1 2025, exceeding consensus estimates [11]. - The company faced challenges due to avian influenza, leading to the depopulation of 3.1 million laying hens, which affected egg supply [10]. - Cal-Maine is expanding its cage-free egg production capacity with a $40 million investment to add five new layer houses, expected to increase capacity by 1 million cage-free hens by summer 2025 [12]. - Despite impressive stock gains, Cal-Maine's stock may be overvalued, trading at $90, with a consensus price target of $67.00, indicating a potential downside [13][14].

Core Insights - Cal-Maine Foods, Inc. (NASDAQ: CALM) reported better than expected quarterly results, attributed to higher egg prices and recent inorganic growth efforts [1] - The company effectively managed recent outbreaks of Highly Pathogenic Avian Influenza (HPAI) [1] Financial Performance - The quarterly results exceeded market expectations, indicating strong financial health [1] - Higher egg prices contributed significantly to the revenue growth [1] Strategic Actions - Recent inorganic efforts have positively impacted the company's performance, suggesting a proactive approach to growth [1] - The company's response to HPAI outbreaks demonstrates effective risk management and operational resilience [1]

Core Insights - Cal-Maine Foods, the largest egg producer in the U.S., reported a significant increase in quarterly sales, driven by rising egg prices and reduced production costs [1][2] - The company achieved sales of $786 million in the first quarter of fiscal 2025, up from $489 million a year ago, exceeding expectations of $705 million [2] - The ongoing avian flu outbreak has reduced the U.S. egg supply, contributing to inflation, with the net average selling price for a dozen eggs rising to $2.392 from $1.589 [3] Financial Performance - Cal-Maine Foods reported a net income of $150 million, or $3.06 per share, compared to $9.26 million, or $0.02 per share, in the same quarter last year [4] - The company's stock price has increased approximately 34% year-to-date, outperforming the S&P 500 index's gain of around 20% [4] Market Conditions - The rise in egg prices has become a significant factor in inflation, influenced by the avian flu outbreak [3] - A decline in production costs, mainly due to lower feed ingredient prices, has positively impacted the company's financial performance [3] Operational Resilience - Despite the severe impact of Hurricane Helen on the southeastern U.S., the company stated that it is unlikely to significantly affect its operations and business [4]

[Part I. Financial Information](index=3&type=section&id=Part%20I.%20Financial%20Information) This section details the company's financial performance, operational analysis, market risk, and internal controls [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The company's financial statements for Q1 FY2025 reflect substantial growth in assets, sales, and net income, driven by favorable market conditions and operational efficiency [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows total assets increased to $2.39 billion, with corresponding rises in liabilities and stockholders' equity Condensed Consolidated Balance Sheet Highlights (in thousands USD) | Account | August 31, 2024 | June 1, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $1,343,479 | $1,241,839 | | **Property, Plant & Equipment, net** | $960,070 | $857,234 | | **Total Assets** | **$2,390,008** | **$2,184,761** | | **Total Current Liabilities** | $325,415 | $227,743 | | **Total Liabilities** | $490,945 | $387,718 | | **Total Stockholders' Equity** | $1,899,063 | $1,797,043 | [Condensed Consolidated Statements of Income](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) The income statement reveals a significant profitability turnaround with net sales surging to $785.9 million and net income reaching $150.0 million Income Statement Summary (in thousands USD, except per share data) | Metric | Thirteen Weeks Ended Aug 31, 2024 | Thirteen Weeks Ended Sep 2, 2023 | | :--- | :--- | :--- | | **Net Sales** | $785,871 | $459,344 | | **Gross Profit** | $247,218 | $45,433 | | **Operating Income (Loss)** | $186,957 | $(6,757) | | **Net Income Attributable to Cal-Maine** | $149,976 | $926 | | **Diluted EPS** | $3.06 | $0.02 | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow significantly increased to $117.5 million, while investing activities, including an acquisition, led to a net decrease in cash Cash Flow Summary (in thousands USD) | Cash Flow Activity | Thirteen Weeks Ended Aug 31, 2024 | Thirteen Weeks Ended Sep 2, 2023 | | :--- | :--- | :--- | | **Net cash provided by operations** | $117,452 | $23,685 | | **Net cash provided by (used in) investing** | $(135,871) | $80,880 | | **Net cash used in financing** | $(37,792) | $(37,046) | | **Net change in cash** | $(56,211) | $67,519 | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail a significant business acquisition, revenue segmentation by product, ongoing legal proceedings, and a subsequent strategic investment - Effective June 28, 2024, the company acquired substantially all commercial shell egg production and processing assets of ISE America, Inc. for cash consideration of **$111.5 million**, including facilities with a capacity of approximately **4.7 million laying hens**[23](index=23&type=chunk)[24](index=24&type=chunk) Revenue by Product Category (in thousands USD) | Product Category | Q1 FY2025 | Q1 FY2024 | | :--- | :--- | :--- | | Conventional shell egg sales | $484,736 | $225,280 | | Specialty shell egg sales | $256,777 | $208,681 | | Egg products | $35,175 | $22,223 | | Other | $9,183 | $3,160 | | **Total** | **$785,871** | **$459,344** | - Subsequent to the quarter end, on September 9, 2024, the company completed a strategic investment in Crepini LLC, capitalizing a new venture, Crepini Foods LLC, with **$6.75 million in cash** for a **51% interest**[48](index=48&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=17&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) MD&A highlights strong Q1 FY2025 performance driven by higher egg prices, increased sales volume, and reduced feed costs, maintaining robust liquidity [Executive Overview](index=19&type=section&id=Executive%20Overview) The executive overview highlights a significant increase in gross profit driven by higher egg prices, increased sales volume, and lower feed costs - Net average selling price per dozen increased to **$2.392** in Q1 FY2025 from **$1.589** in the prior-year period, primarily due to HPAI outbreaks decreasing the national layer hen flock and thus reducing supply[66](index=66&type=chunk) - Total dozens sold increased by **13.5%** compared to the prior year, boosted by the acquisitions of ISE and Fassio, which offset temporary production losses from HPAI outbreaks at Cal-Maine's Kansas and Texas facilities[67](index=67&type=chunk) - Farm production costs per dozen decreased by **11.7%** year-over-year, mainly due to a **17.3%** reduction in feed costs per dozen produced[68](index=68&type=chunk) [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Results of operations show net sales surged to $785.9 million, driven by price and volume increases, leading to expanded gross profit margins Shell Egg Sales Analysis (Q1 FY2025 vs Q1 FY2024, per dozen) | Category | Net Average Selling Price per Dozen | Dozens Sold (thousands) | | :--- | :--- | :--- | | **Conventional** | $2.424 (up 95.3%) | 199,989 (up 10.2%) | | **Specialty** | $2.335 (up 2.5%) | 109,990 (up 20.1%) | | **All Shell Eggs** | **$2.392 (up 50.5%)** | **309,979 (up 13.5%)** | Farm Production Costs (per dozen produced, USD) | Cost Component | Q1 FY2025 | Q1 FY2024 | % Change | | :--- | :--- | :--- | :--- | | Feed | $0.494 | $0.597 | (17.3)% | | Other | $0.421 | $0.439 | (4.1)% | | **Total** | **$0.915** | **$1.036** | **(11.7)%** | - Costs for outside egg purchases increased significantly due to a **71.5%** rise in the average cost per dozen and a **67.5%** increase in the volume of dozens purchased, necessitated by HPAI-related production losses[83](index=83&type=chunk) [Liquidity and Capital Resources](index=24&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with $1.0 billion in working capital, no long-term debt, and sufficient resources for future operations and capital projects - Working capital remained strong at **$1.0 billion** at the end of the quarter, with a current ratio of **4.1**[94](index=94&type=chunk) - A cash dividend of approximately **$50.0 million**, or **$1.019 per share**, will be paid for the first fiscal quarter of 2025[100](index=100&type=chunk) Material Construction Projects (as of Aug 31, 2024, in thousands USD) | Project Type | Projected Completion | Projected Cost | Remaining Cost | | :--- | :--- | :--- | :--- | | Cage-Free Layer & Pullet Houses | Fiscal 2025 | $81,429 | $7,484 | | Dexter, MO Renovations | Fiscal 2025 | $6,204 | $1,500 | | Feed Mills | Fiscal 2026 | $16,593 | $12,028 | | Cage-Free Layer & Pullet Houses | Fiscal 2026 | $135,905 | $20,485 | | **Total** | | **$240,131** | **$41,497** | [Quantitative and Qualitative Disclosures About Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes in its exposure to market risk during the first quarter of fiscal 2025 from prior disclosures - There have been no material changes in the company's exposure to market risk during the thirteen weeks ended August 31, 2024[105](index=105&type=chunk) [Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter - The company's CEO and CFO concluded that disclosure controls and procedures were effective as of August 31, 2024[106](index=106&type=chunk) - There were no material changes to the company's internal control over financial reporting during the quarter[107](index=107&type=chunk) [Part II. Other Information](index=27&type=section&id=Part%20II.%20Other%20Information) This section covers legal proceedings, risk factors, equity sales, and exhibits [Legal Proceedings](index=27&type=section&id=Item%201.%20Legal%20Proceedings) The company refers to the detailed discussion of its legal proceedings as disclosed in Note 10 of the Notes to Condensed Consolidated Financial Statements - For information on legal proceedings, the report refers to Note 10 in the financial statements section of the Form 10-Q[108](index=108&type=chunk) [Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K - No material changes in risk factors were reported compared to the company's 2024 Annual Report[109](index=109&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=27&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q1 FY2025, the company repurchased 502 shares of common stock at an average price of $66.86 per share to satisfy tax withholding obligations Q1 FY2025 Share Repurchases (USD) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | 06/30/24 to 07/27/24 | 502 | $66.86 | | **Total** | **502** | **$66.86** | [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the quarterly report, including corporate documents and officer certifications - The report includes standard exhibits such as officer certifications and Inline XBRL data files[112](index=112&type=chunk)

Financial Performance - Quarterly net sales reached $785.9 million, a significant increase from $459.3 million in the same period last year[5] - Net income for the first quarter was $150.0 million, or $3.06 per diluted share, compared to $926,000, or $0.02 per diluted share, for the first quarter of fiscal 2024[6] - The net average selling price per dozen of shell eggs was $2.392, compared to $1.589 in the prior year, reflecting a year-over-year increase of 50.5%[6] Sales and Production - Total dozens of shell eggs sold increased to 310.0 million, up from 273.1 million dozens sold in the first quarter of fiscal 2024, representing a growth of 13.5%[5] - Specialty egg volumes increased by 20.1%, with 110.0 million dozens sold compared to 91.6 million dozens in the first quarter of fiscal 2024[5] - Farm production costs per dozen were 11.7% lower compared to the prior-year period, primarily due to favorable commodity pricing for key feed ingredients[6] Strategic Investments - Cal-Maine Foods has made strategic investments in Meadowcreek Foods and Crepini Foods to enhance its product portfolio with value-added egg products[2] - The company plans to expand capacity for cage-free and specialty egg production through investments in innovative products and facilities[10] Dividends and Shareholder Returns - The company declared a cash dividend of approximately $50.0 million, or $1.02 per share, reflecting its established dividend policy[1] Asset and Liability Changes - Total assets increased to $2,390,008 thousand, up from $2,184,761 thousand year-over-year, representing a growth of approximately 9.4%[16] - Cash and short-term investments decreased to $753,590 thousand from $812,377 thousand, a decline of about 7.2%[16] - Accounts payable and accrued expenses rose to $275,444 thousand, compared to $189,983 thousand, reflecting an increase of approximately 45%[16] - Stockholders' equity increased to $1,899,063 thousand from $1,797,043 thousand, showing a growth of about 5.7%[16] - Current liabilities increased to $325,415 thousand from $227,743 thousand, marking an increase of approximately 43%[16] - Dividends payable rose to $49,971 thousand from $37,760 thousand, an increase of about 32%[16] - Receivables, net increased significantly to $282,551 thousand from $162,442 thousand, representing a growth of approximately 74%[16] - Inventories, net increased to $293,182 thousand from $261,782 thousand, reflecting an increase of about 11.9%[16] - Deferred income taxes and other liabilities increased slightly to $165,530 thousand from $159,975 thousand, a growth of about 3.5%[16] - Prepaid expenses and other current assets increased to $14,156 thousand from $5,238 thousand, a significant increase of approximately 169%[16] Impact of Hurricane Helene - The impact of Hurricane Helene is being evaluated, but initial assessments indicate minimal loss of production assets[3]

Partnership and Collaboration - Revitalist Lifestyle and Wellness Ltd partners with Sama Therapeutics to expand access to mental health care through novel technology, including the release of a proprietary Digital Human Artificial Intelligence Agent [1] - The collaboration aims to enhance mental health assessments globally by integrating advanced AI technology [1][4] Technology and Innovation - The AI Agent, modeled after Revitalist CEO Kathryn Walker, engages patients in conversational dialogue and implements the proprietary Federal Unit Scale (FUS) for mental health screening [2] - The FUS was rigorously validated through an analysis of 11,798 participants, demonstrating strong psychometric properties [2] - Sama's AI Agent platform can create lifelike digital human avatars of healthcare providers, capable of communicating in over 100 languages and capturing audiovisual biomarkers for precise data collection [3] Impact and Vision - The partnership is expected to redefine mental health care accessibility and engagement on a global scale by integrating medically and ethically sound AI in neuropsychiatry [3][4] - The collaboration aims to deliver the highest standard of patient care and clinical research with exceptional efficiency [4] Company Overview - Revitalist Lifestyle and Wellness Ltd is a mental health and wellness company focused on comprehensive care in the ketamine wellness space, operating through physical locations and virtual offices across 35 states [5] - Sama Therapeutics is a leading innovator in AI-powered precision medicine, utilizing its proprietary iMAGiNE™ platform to deliver personalized brain health assessments [6] - Sama integrates generative AI with computational life sciences to redefine "software as a medical device" across various disorders [7] - Sama's mission is to unlock brain health through integrative neurotechnology, transforming psychiatric and neurological medicine [8]

Group 1 - Revitalist Lifestyle and Wellness Ltd. is sponsoring The American Legion's 105th National Convention, which will take place from August 23-29, 2024, and is focused on addressing veteran suicides [1][2] - The company will provide two psychedelic retreats, free consultations for ketamine and psychedelic therapies, and donate 100% of sales during the event to support veterans in need [1][4] - Revitalist's CEO, Kathryn A. Walker, will be present at the convention offering wellness services and educational materials, with all proceeds directed towards veteran treatment [4][8] Group 2 - The convention gathers delegates from all 55 departments across the U.S. and aims to amend the Legion's constitution, enact programs, and elect national leaders [2] - A key initiative at the convention is the "Be the One" campaign, which aims to reduce the rate of veteran suicides, currently at 22 per day, by promoting mental health awareness [3] Group 3 - Veterans can sign up for a chance to win a psychedelic retreat and schedule free consultations through Revitalist's website [6][5] - For those unable to attend, Revitalist will extend support online, with all supplement and book purchases made during the convention period contributing to veteran treatment [7] Group 4 - The American Legion, established in 1919, is the largest wartime veterans service organization with over 1.6 million members, dedicated to supporting veterans and advocating for their well-being [9] - Revitalist is positioned as a mental health and wellness company specializing in ketamine therapies, operating both physical locations and virtual offices across the USA [10][11]

Core Insights - Revitalist Lifestyle and Wellness Ltd. is actively participating in the AANA Annual Congress, focusing on the integration of psychedelics in anesthesia practices [2][5]. Group 1: Event Details - Kathryn A. Walker, CEO of Revitalist, will present at the AANA Annual Congress from August 2-6, 2024, in San Diego [2]. - Walker's session titled "Entering the World of Psychedelics as an Anesthesia Professional" is scheduled for August 5, 2024, from 3:30 PM to 4:30 PM PT [3]. Group 2: Session Content - The session will explore the emerging field of psychedelic medicines and their applications in anesthesia, including medication delivery techniques and therapeutic communication styles [4]. - Key learning objectives include identifying psychedelic medicines and their legal approval dates, understanding their pharmacologic nature, and discussing outpatient community practices [4]. Group 3: Company Overview - Revitalist Lifestyle and Wellness Ltd. specializes in mental health and wellness, particularly in the ketamine wellness space, offering innovative and evidence-based services [7]. - The company operates through physical locations and virtual offices across the United States and the British Virgin Islands, positioning itself at the forefront of the psychedelic space [7][8].

Core Insights - Kathryn A. Walker's new book "Inflamed: Theory" explores the relationship between mental health and neurological/inflammatory processes in the brain, challenging traditional mental health theories and proposing innovative treatment approaches [1][2][5] - The book emphasizes the integration of psychedelic medicine into mainstream mental health practices, reflecting a shift towards advanced mental health interventions [2][5] Company Overview - Revitalist Lifestyle and Wellness Ltd. is led by Kathryn A. Walker, who has a strong background in anesthesia and psychiatric care, positioning the company as a proponent of innovative mental health therapies [2][5] - The company is actively promoting the presale of "Inflamed: Theory," indicating a strategic move to enhance its presence in the mental health sector [5] Industry Implications - The book discusses the disruptive potential of psychedelics in mental health, suggesting a transformative impact on treatment methodologies [2][5] - Walker's insights aim to provide a comprehensive understanding of the evolving landscape of mental health care, highlighting the importance of cutting-edge therapies [5]